RPRX


Royalty Pharma Ramps Up Dividend By 13%

Royalty Pharma announced a 13% hike in its quarterly dividend to $0.17 per share from $0.

Monday’s Biotech News: Valeant Pharmaceuticals Intl Inc (VRX), Repros Therapeutics Inc (RPRX)

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is putting more efforts to repay the term loan debt under its Senior Secured Credit Facility. This morning, the …

Stock Update (NASDAQ:RPRX): Here’s Why Repros Therapeutics Inc Shares Are Rising 14%

Repros Therapeutics Inc (NASDAQ:RPRX) investors have a reason to smile this afternoon, after the drug maker reported positive topline results for both its pooled …

Stock Update (NASDAQ:RPRX): Repros Therapeutics Inc Announces FDA Advisory Committee Meeting To Discuss Secondary Hypogonadism

Repros Therapeutics Inc (NASDAQ:RPRX) noted that it will participate as a sponsor in a forthcoming public advisory committee meeting of the Bone, Reproductive …

Company Update (NASDAQ:RPRX): Repros Therapeutics Inc Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism

Repros Therapeutics Inc (NASDAQ:RPRX) announced that, as anticipated, it has activated the process for obtaining a marketing authorization (MAA) for enclomiphene in the treatment …

Stock Update (NASDAQ:RPRX): Repros Therapeutics Inc Provides Phase 2 Results Showing Positive Outcomes for Oral Proellex(R) in Women With Moderate to Severe Endometriosis

Repros Therapeutics Inc (NASDAQ:RPRX) provided the results of the first course of treatment from Repros’ ongoing study of Proellex® for the treatment of …

Thursday’s Morning Insights: Repros Therapeutics Inc (RPRX), Keryx Biopharmaceuticals (KERX), and Conn’s Inc (CONN)

Repros Therapeutics Inc (NASDAQ:RPRX) is soaring nearly 19% this morning to $2.01 following yesterday’s positive news that provided an update on the company’s …

Repros Therapeutics Inc (RPRX) Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men

Repros Therapeutics Inc (NASDAQ:RPRX) announced that it remains on track for submission of a European centralized marketing authorization application (MAA) for enclomiphene for …

Thursday Morning’s Market Insights: Repros Therapeutics Inc (RPRX), Energy XXI Ltd (EXXI), Chipotle Mexican Grill, Inc. (CMG)

Repros Therapeutics Inc (NASDAQ:RPRX) is up 5% in pre-market trading, adding to their 175% increase yesterday after the company announced positive results from …

Wednesday Morning’s Market Insights: Linn Energy LLC (LINE), Repros Therapeutics Inc (RPRX), JPMorgan Chase & Co. (JPM), and Oculus Innovative Sciences, Inc. (OCLS)

Linn Energy LLC (NASDAQ:LINE) is down more than 5% in pre-market to $0.45 after major oil producers failed to reach an agreement regarding …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts